Cartesian Therapeutics, Inc. Research and Development Expense
Cartesian Therapeutics, Inc. (RNAC) reported Research and Development Expense of $20.43 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Cartesian Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $20.43M, a 37.41% increase year-over-year.
- Cartesian Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $19.46M, a 32.64% increase year-over-year.
- Cartesian Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $14.69M, a 29.92% increase year-over-year.
- Cartesian Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $13.80M, a 21.07% increase year-over-year.
- Cartesian Therapeutics, Inc. research and development expense for fiscal 2025 was $58.03M, a 28.66% increase from fiscal 2024.
- Cartesian Therapeutics, Inc. research and development expense for fiscal 2024 was $45.10M, a 36.70% decline from fiscal 2023.
- Cartesian Therapeutics, Inc. research and development expense for fiscal 2023 was $71.26M, a 1.54% decline from fiscal 2022.
- Cartesian Therapeutics, Inc. research and development expense for fiscal 2022 was $72.38M, a 5.30% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $20.43M 10-Q · filed 2026-08-06 | $39.89M 10-Q · filed 2026-08-06 | $54.58M derived: sum of 3 quarters · filed 2026-08-06 | $68.39M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $19.46M 10-Q · filed 2026-04-30 | $34.15M derived: sum of 2 quarters · filed 2026-04-30 | $47.95M derived: sum of 3 quarters · filed 2026-04-30 | $62.82M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $14.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $28.49M derived: sum of 2 quarters · filed 2026-03-09 | $43.36M derived: sum of 3 quarters · filed 2026-08-06 | $58.03M 10-K · filed 2026-03-09 | |
| 2025-09-30 | $13.80M 10-Q · filed 2025-11-06 | $28.67M derived: sum of 2 quarters · filed 2026-08-06 | $43.34M 10-Q · filed 2025-11-06 | $54.65M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $14.87M 10-Q · filed 2026-08-06 | $29.54M 10-Q · filed 2026-08-06 | $40.85M derived: sum of 3 quarters · filed 2026-08-06 | $52.25M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $14.67M 10-Q · filed 2026-04-30 | $25.98M derived: sum of 2 quarters · filed 2026-04-30 | $37.38M derived: sum of 3 quarters · filed 2026-04-30 | $50.04M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $11.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $22.71M derived: sum of 2 quarters · filed 2026-03-09 | $35.37M derived: sum of 3 quarters · filed 2026-03-09 | $45.10M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $11.40M 10-Q · filed 2025-11-06 | $24.06M derived: sum of 2 quarters · filed 2025-11-06 | $33.80M 10-Q · filed 2025-11-06 | $55.65M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $12.66M 10-Q · filed 2025-08-07 | $22.40M 10-Q · filed 2025-08-07 | $44.25M derived: sum of 3 quarters · filed 2025-08-07 | $57.25M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $9.74M 10-Q · filed 2025-05-08 | $31.59M derived: sum of 2 quarters · filed 2025-05-08 | $44.59M derived: sum of 3 quarters · filed 2025-05-08 | $62.37M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $21.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $34.85M derived: sum of 2 quarters · filed 2025-03-13 | $52.64M derived: sum of 3 quarters · filed 2025-03-13 | $71.26M 10-K · filed 2025-03-13 | $71.84M 10-K · filed 2024-03-07 |
| 2023-09-30 | $13.00M 10-Q · filed 2024-11-07 | $30.78M derived: sum of 2 quarters · filed 2024-11-07 | $49.41M 10-Q · filed 2024-11-07 | $68.38M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $17.78M 10-Q · filed 2024-08-08 | $36.41M 10-Q · filed 2024-08-08 | $55.37M derived: sum of 3 quarters · filed 2024-08-08 | $71.91M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $18.62M 10-Q · filed 2024-05-08 | $37.59M derived: sum of 2 quarters · filed 2024-05-08 | $54.13M derived: sum of 3 quarters · filed 2024-05-08 | $73.31M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | $18.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $35.51M derived: sum of 2 quarters · filed 2024-03-07 | $54.69M derived: sum of 3 quarters · filed 2024-03-07 | $72.38M 10-K · filed 2024-03-07 | |
| 2022-09-30 | $16.54M 10-Q · filed 2023-11-13 | $35.72M derived: sum of 2 quarters · filed 2023-11-13 | $53.41M 10-Q · filed 2023-11-13 | $73.73M derived: sum of 4 quarters · filed 2024-03-07 | |
| 2022-06-30 | $19.18M 10-Q · filed 2023-08-17 | $36.87M 10-Q · filed 2023-08-17 | $57.19M derived: sum of 3 quarters · filed 2024-03-07 | $78.14M derived: sum of 4 quarters · filed 2024-03-07 | |
| 2022-03-31 | $17.69M 10-Q · filed 2023-05-04 | $38.01M derived: sum of 2 quarters · filed 2024-03-07 | $58.96M derived: sum of 3 quarters · filed 2024-03-07 | $73.42M derived: sum of 4 quarters · filed 2024-03-07 | |
| 2021-12-31 | $20.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $41.27M derived: sum of 2 quarters · filed 2024-03-07 | $55.73M derived: sum of 3 quarters · filed 2024-03-07 | $68.74M 10-K · filed 2024-03-07 | |
| 2021-09-30 | $20.95M 10-Q · filed 2022-11-03 | $35.41M derived: sum of 2 quarters · filed 2022-11-03 | $48.42M 10-Q · filed 2022-11-03 | $63.51M derived: sum of 4 quarters · filed 2023-03-02 | |
| 2021-06-30 | $14.46M 10-Q · filed 2022-08-08 | $27.47M 10-Q · filed 2022-08-08 | $42.56M derived: sum of 3 quarters · filed 2023-03-02 | $56.52M derived: sum of 4 quarters · filed 2023-03-02 | |
| 2021-03-31 | $13.00M 10-Q · filed 2022-05-05 | $28.09M derived: sum of 2 quarters · filed 2023-03-02 | $42.05M derived: sum of 3 quarters · filed 2023-03-02 | $52.78M derived: sum of 4 quarters · filed 2023-03-02 | |
| 2020-12-31 | $15.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $29.05M derived: sum of 2 quarters · filed 2023-03-02 | $39.78M derived: sum of 3 quarters · filed 2023-03-02 | $54.51M 10-K · filed 2023-03-02 | |
| 2020-09-30 | $13.96M 10-Q · filed 2021-11-09 | $24.69M derived: sum of 2 quarters · filed 2021-11-09 | $39.41M 10-Q · filed 2021-11-09 | $54.57M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2020-06-30 | $10.73M 10-Q · filed 2021-08-12 | $25.45M 10-Q · filed 2021-08-12 | $40.61M derived: sum of 3 quarters · filed 2022-03-10 | $48.71M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2020-03-31 | $14.72M 10-Q · filed 2021-05-13 | $29.88M derived: sum of 2 quarters · filed 2022-03-10 | $37.98M derived: sum of 3 quarters · filed 2022-03-10 | $50.11M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2019-12-31 | $15.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $23.26M derived: sum of 2 quarters · filed 2022-03-10 | $35.39M derived: sum of 3 quarters · filed 2022-03-10 | $42.74M 10-K · filed 2022-03-10 | |
| 2019-09-30 | $8.10M 10-Q · filed 2020-11-05 | $20.24M derived: sum of 2 quarters · filed 2020-11-05 | $27.59M 10-Q · filed 2020-11-05 | $37.85M derived: sum of 4 quarters · filed 2021-03-12 | |
| 2019-06-30 | $12.13M 10-Q · filed 2020-08-06 | $19.49M 10-Q · filed 2020-08-06 | $29.74M derived: sum of 3 quarters · filed 2021-03-12 | $41.63M derived: sum of 4 quarters · filed 2021-03-12 | |
| 2019-03-31 | $7.35M 10-Q · filed 2020-05-07 | $17.61M derived: sum of 2 quarters · filed 2021-03-12 | $29.49M derived: sum of 3 quarters · filed 2021-03-12 | $43.90M derived: sum of 4 quarters · filed 2021-03-12 | |
| 2018-12-31 | $10.26M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $22.14M derived: sum of 2 quarters · filed 2021-03-12 | $36.55M derived: sum of 3 quarters · filed 2021-03-12 | $47.69M 10-K · filed 2021-03-12 | |
| 2018-09-30 | $11.88M 10-Q · filed 2019-11-08 | $26.29M derived: sum of 2 quarters · filed 2019-11-08 | $37.43M 10-Q · filed 2019-11-08 | $51.05M derived: sum of 4 quarters · filed 2020-03-12 | |
| 2018-06-30 | $14.41M 10-Q · filed 2019-08-08 | $25.55M 10-Q · filed 2019-08-08 | $39.17M derived: sum of 3 quarters · filed 2020-03-12 | $48.67M derived: sum of 4 quarters · filed 2020-03-12 | |
| 2018-03-31 | $11.14M 10-Q · filed 2019-05-09 | $24.76M derived: sum of 2 quarters · filed 2020-03-12 | $34.27M derived: sum of 3 quarters · filed 2020-03-12 | $45.26M derived: sum of 4 quarters · filed 2020-03-12 | |
| 2017-12-31 | $13.62M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $23.13M derived: sum of 2 quarters · filed 2020-03-12 | $34.12M derived: sum of 3 quarters · filed 2020-03-12 | $45.16M 10-K · filed 2020-03-12 | |
| 2017-09-30 | $9.50M 10-Q · filed 2018-11-08 | $20.50M derived: sum of 2 quarters · filed 2018-11-08 | $31.54M 10-Q · filed 2018-11-08 | $42.58M derived: sum of 4 quarters · filed 2019-03-15 | |
| 2017-06-30 | $10.99M 10-Q · filed 2018-08-08 | $22.04M 10-Q · filed 2018-08-08 | $33.07M derived: sum of 3 quarters · filed 2019-03-15 | $39.09M derived: sum of 4 quarters · filed 2019-03-15 | |
| 2017-03-31 | $11.04M 10-Q · filed 2018-05-09 | $22.08M derived: sum of 2 quarters · filed 2019-03-15 | $28.10M derived: sum of 3 quarters · filed 2019-03-15 | $34.10M derived: sum of 4 quarters · filed 2019-03-15 | |
| 2016-12-31 | $11.03M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $17.05M derived: sum of 2 quarters · filed 2019-03-15 | $23.05M derived: sum of 3 quarters · filed 2019-03-15 | $29.70M 10-K · filed 2019-03-15 | |
| 2016-09-30 | $6.02M 10-Q · filed 2017-11-07 | $12.02M derived: sum of 2 quarters · filed 2017-11-07 | $18.67M 10-Q · filed 2017-11-07 | $25.88M derived: sum of 4 quarters · filed 2018-03-15 | |
| 2016-06-30 | $6.00M 10-Q · filed 2017-08-11 | $12.65M 10-Q · filed 2017-08-11 | $19.86M derived: sum of 3 quarters · filed 2018-03-15 | $25.34M derived: sum of 4 quarters · filed 2018-03-15 | |
| 2016-03-31 | $6.65M 10-Q · filed 2017-05-11 | $13.86M derived: sum of 2 quarters · filed 2018-03-15 | $19.34M derived: sum of 3 quarters · filed 2018-03-15 | $24.66M derived: sum of 4 quarters · filed 2018-03-15 | |
| 2015-12-31 | $7.21M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $12.69M derived: sum of 2 quarters · filed 2018-03-15 | $18.01M derived: sum of 3 quarters · filed 2018-03-15 | $22.98M 10-K · filed 2018-03-15 | |
| 2015-09-30 | $5.48M 10-Q · filed 2016-11-10 | $10.80M derived: sum of 2 quarters · filed 2016-11-10 | $15.77M 10-Q · filed 2016-11-10 | ||
| 2015-06-30 | $5.31M 10-Q · filed 2016-08-09 | $10.29M 10-Q · filed 2016-08-09 | |||
| 2014-12-31 | $10.49M 10-K · filed 2017-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |